CELC
Price
$88.28
Change
-$4.19 (-4.53%)
Updated
Jun 5 closing price
Capitalization
4.31B
60 days until earnings call
Intraday BUY SELL Signals
ERAS
Price
$11.97
Change
-$1.30 (-9.80%)
Updated
Jun 5 closing price
Capitalization
3.72B
60 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CELC vs ERAS

Header iconCELC vs ERAS Comparison
Open Charts CELC vs ERASBanner chart's image
CELC vs ERAS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CELC vs. ERAS commentary
Jun 08, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELC is a Hold and ERAS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 08, 2026
Stock price -- (CELC: $88.28 vs. ERAS: $11.97)
Brand notoriety: CELC and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELC: 128% vs. ERAS: 84%
Market capitalization -- CELC: $4.31B vs. ERAS: $3.72B
CELC [@Biotechnology] is valued at $4.31B. ERAS’s [@Biotechnology] market capitalization is $3.72B. The market cap for tickers in the [@Biotechnology] industry ranges from $113.41B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELC’s FA Score shows that 0 FA rating(s) are green whileERAS’s FA Score has 0 green FA rating(s).

  • CELC’s FA Score: 0 green, 5 red.
  • ERAS’s FA Score: 0 green, 5 red.
According to our system of comparison, CELC is a better buy in the long-term than ERAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELC’s TA Score shows that 4 TA indicator(s) are bullish while ERAS’s TA Score has 5 bullish TA indicator(s).

  • CELC’s TA Score: 4 bullish, 6 bearish.
  • ERAS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than CELC.

Price Growth

CELC (@Biotechnology) experienced а -33.56% price change this week, while ERAS (@Biotechnology) price change was -6.78% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.86%. For the same industry, the average monthly price growth was -7.98%, and the average quarterly price growth was -1.75%.

Reported Earning Dates

CELC is expected to report earnings on Aug 06, 2026.

ERAS is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Biotechnology (-7.86% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CELC($4.31B) has a higher market cap than ERAS($3.72B). ERAS YTD gains are higher at: 221.774 vs. CELC (-11.490). ERAS has higher annual earnings (EBITDA): -130.68M vs. CELC (-172.66M). CELC has more cash in the bank: 387M vs. ERAS (244M). ERAS has less debt than CELC: ERAS (46M) vs CELC (323M). CELC (0) and ERAS (0) have equivalent revenues.
CELCERASCELC / ERAS
Capitalization4.31B3.72B116%
EBITDA-172.66M-130.68M132%
Gain YTD-11.490221.774-5%
P/E RatioN/AN/A-
Revenue00-
Total Cash387M244M159%
Total Debt323M46M702%
FUNDAMENTALS RATINGS
CELC: Fundamental Ratings
CELC
OUTLOOK RATING
1..100
62
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
PROFIT vs RISK RATING
1..100
43
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
36
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CELCERAS
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
82%
Momentum
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
87%
MACD
ODDS (%)
Bearish Trend 3 days ago
75%
Bullish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 18 days ago
84%
Bullish Trend 7 days ago
83%
Declines
ODDS (%)
Bearish Trend 5 days ago
84%
Bearish Trend 5 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
89%
Bearish Trend 3 days ago
83%
Aroon
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
CELC
Daily Signal:
Gain/Loss:
ERAS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SBIT67.906.37
+10.35%
ProShares UltraShort Bitcoin ETF
NBTR49.74-0.12
-0.24%
Neuberger Berman Total Return Bond ETF
DLN95.75-1.15
-1.19%
WisdomTree US LargeCap Dividend ETF
FFND31.64-0.77
-2.37%
One Global ETF
DDM62.28-1.76
-2.75%
ProShares Ultra Dow30

CELC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELC has been closely correlated with IMA. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if CELC jumps, then IMA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELC
1D Price
Change %
CELC100%
-4.53%
IMA - CELC
78%
Closely correlated
-0.70%
SLXN - CELC
50%
Loosely correlated
-5.85%
ABOS - CELC
44%
Loosely correlated
-6.11%
KYMR - CELC
42%
Loosely correlated
-0.64%
TRDA - CELC
42%
Loosely correlated
-9.00%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with REPL. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-9.80%
REPL - ERAS
42%
Loosely correlated
-4.05%
AMLX - ERAS
39%
Loosely correlated
-6.92%
MLTX - ERAS
36%
Loosely correlated
-4.38%
RZLT - ERAS
36%
Loosely correlated
-5.76%
CELC - ERAS
36%
Loosely correlated
-4.53%
More